Clinical Trial Update: Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease [Phase 2]

View source ↗

Summary

This update reports the completion of a long-term Phase 2 clinical trial evaluating Semapimod (CNI-1493) for Crohn's disease. The trial was sponsored by Ferring…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Semapimod (CNI-1493)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED